Monthly Archives: March 2013

Azerra for mantle cell lymphoma

Azerra (ofatumumab) is a new antibiody against Chronic lymphocytic leukemia( CLL).  Preclinical data suggest that it might be more effective than Rituxan in variety of lymphomas.  In early clinical trials, ofatumumab demonstrated single-agent activity against chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphomas. It was approved by the US Food and Drug Administration for the treatment of CLL that is resistant to both fludarabine

Read more
Afinitor for prostate cancer

Afinitor s is currently in clinical trials for prostate cancer and only preliminary information is available.  For example, it is in the phase II study: Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer,  NCT00976755. Several studies have been performed and published.  A phase II study (Templeton et al., 2011) investigating the activity of everolimus 10mg/daily as first-line treatment found that in 37 enrolled patients,

Read more
Afinitor for Hodgkin’s

Afinitor is a new drug that ahs effects on a pathway important in Hodgkin's disease. A recent study showed soverall response of  47% (95% CI: 24-71%). Four responders remained progression free at 12 months. Several studies of combinations with everolimus for Hodgkin's are lsited on There is also the study: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and

Read more
Everolimus for Hodgkin’s – pro

Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3-kinase/mTOR signal transduction pathway has been demonstrated to be activated in Hodgkin lymphoma (HL) and there was speculation that everolimus might be effective for this disease. Johnston et al studied everolimus in 19 patient. Patients had received a median of six prior therapies (range, 3-14) and 84% had undergone

Read more
Flector patch for cancer pain

Flector Patch is a topical  non-steroidal(NSAID) drug diclofenac. Diclofenac has antiinflammatory, analgesic, and anti-fever effects. Each FLECTOR® Patch measures approximately 4 inches by 5.5 inches and contains 180-mg of diclofenac. The recommended dose of FLECTOR® Patch is one patch to the most painful area twice a day (12 hours at a time). FLECTOR® Patch should be applied to intact or non-damaged skin. Some physicians feel that these patches

Read more
Flector patch for painful metastases – pro

Flector Patch(diclofenac) is a topical  non-steroidal(NSAID) drug diclofenac. Diclofenac has anti-inflammatory, analgesic, and antipyretic properties by inhibiting the enzyme cyclooxegenase (COX) and decreasing the formation of prostaglandins, thromboxanes, and prostacyclin. The oral version is Voltaren. Each FLECTOR® Patch measures approximately 4 inches by 5.5 inches and contains 180-mg of diclofenac epolamine. The recommended dose of FLECTOR®

Read more
Abraxane and Avastin for melanoma – pro
Handsome doctor talking with his patient for the annual check-up

Metastatic melanoma responds poorly to chemotherapy with the main drugs being temozolomide or dacarbazine after failure of immunotherapy with ipilimumab or vaccination. However, Abraxane has been reported to have single agent activity. This response rate is higher than observed previously with paclitaxel or docetaxel suggesting that this formulation of paclitaxel may be more active than the conventional form. Among the 37 chemotherapy-naive patients,

Read more
Zolinza for Hodgkin’s

Current chemotherapy drugs are very effective for Hodgkin's  lymphomas but patients who relapse after receiving them don;t do as well. This is because the cancers develop resistance to the se drugs. Zolinza is a new drug approved in the USA for the treatment of cutaneous(skin) T-cell lymphoma who have progressive, persistent or recurrent disease  or following two systemic therapies. It may be effective for Hodgkin's. For Hodgkin's, a phase

Read more
Vorinostat for Hodgkin’s – pro
doc checking glands

Current front-line chemotherapy drugs are very effective against Hodgkin's  lymphoma but patients who relapse after receiving them are less likely to achieve long-term, disease-free survival with current salvage therapies. This is because Hodgkin's develops resistance to the drugs or the tumor's biology changes in some way to reduce their effectiveness. This led to researchers testing newly released drugs for this purpose. Zolinza is approved

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/archive.php on line 56